CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I

  1. Zabaleta, N.
  2. Barberia, M.
  3. Martin-Higueras, C.
  4. Zapata-Linares, N.
  5. Betancor, I.
  6. Rodriguez, S.
  7. Martinez-Turrillas, R.
  8. Torella, L.
  9. Vales, A.
  10. Olagüe, C.
  11. Vilas-Zornoza, A.
  12. Castro-Labrador, L.
  13. Lara-Astiaso, D.
  14. Prosper, F.
  15. Salido, E.
  16. Gonzalez-Aseguinolaza, G.
  17. Rodriguez-Madoz, J.R.
Journal:
Nature Communications

ISSN: 2041-1723

Year of publication: 2018

Volume: 9

Issue: 1

Type: Article

DOI: 10.1038/S41467-018-07827-1 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus